TrialBMC medicine2024

Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.

Li Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.